Negocie Vir Biotechnology VIR

Venda
 Comprar

Gráfico VirBiotechnology ao vivo

5m 15m 30m 1h 4h 1d 1w

Fundamentos do instrumento

Weekly Search
Weekly
Daily
Data Fechar Mudança Alteração (%): Abertura Max Min

VirBiotechnology news

Últimas notícias

Mostrar mais
Liam James 2025 Jul 25, 10:20

ECB Rate Cut Expectations Revised Amid Economic Resilience

Ava Grace 2025 Jul 25, 09:20

Hedge Funds Advise Buying Protection Against Potential Stock Market Downturn

Liam James 2025 Jul 25, 08:20

Federal Funds Rate vs. SOFR: Liquidity Measurement Debate in US Financial System

Ava Grace 2025 Jul 25, 07:20

Musk Praises Tesla Autopilot Performance in China Test, Sparking Debate

Emma Rose 2025 Jul 25, 06:20

Europe Offers Iran Extension on Sanctions Deadline Amid Nuclear Program Concerns

Noah Lee 2025 Jul 25, 05:20

BOJ Rate Hike Outlook: US Trade Deal Creates Space, But Challenges Remain

Noah Lee 2025 Jul 25, 04:20

Tesla Stock Plummets After Musk Warns of 'Tough' Times Under Trump Policies

Sophia Claire 2025 Jul 25, 01:20

France to Recognize Palestine State at UN, Drawing Israeli Condemnation

Info

Spread

0.05

Spread (%)

0.8913 %

Alavancagem

1:10

Juro overnight, Compra

-0.0597 %

Juro overnight, Venda

-0.0292 %

Moeda

USD

Horários de Negociação

Mercados fechados

Segunda-feira

13:31 - 19:59

Terça-feira

13:31-19:59

Quarta-feira

13:31-19:59

Quinta-feira

13:31-19:59

Sexta-feira

13:31-19:59

Análise e estatística

Abertura

---

Fechamento anterior

---

Alta/baixa em 52 semanas

--- – ---

Capitalização de mercado

781044736

Ações em circulação

138238000

Data dos rendimentos (Próxima)

0000-00-00

Rendim Divid

Data Ex-Dividendos

Taxa anual futura de dividendos

0

Rendimento anual futuro de dividendos

0

EPS

-4.23

Saiba mais sobre este instrumento

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Instrumentos relacionados

Ativo
Venda
Comprar
Alteração (%):

Negociar agora

Negociar agora

Negociar agora

Negociar agora
Instrumentos relacionados

latest_education_articles

Mostrar mais
Trustpilot